mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

@article{Statz2016mTORII,
  title={mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review},
  author={Cara M. Statz and Sara Elizabeth Patterson and Susan M. Mockus},
  journal={Targeted Oncology},
  year={2016},
  volume={12},
  pages={47-59}
}
The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes. Trials included in the study were identified through… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

  • International journal of molecular sciences
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC)

ME Gross TBD, DI Quinn, +3 authors DB. Agus
  • J Clin Oncol. 2015;33(suppl; abstr 5066)
  • 2017
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

  • Bioorganic & medicinal chemistry letters
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC).

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…